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Abstract
The endosomal-lysosomal system is made up of a set of intracellular membranous compartments that dynamically
interconvert, which is comprised of early endosomes, recycling endosomes, late endosomes, and the lysosome. In
addition, autophagosomes execute autophagy, which delivers intracellular contents to the lysosome. Maturation of
endosomes and/or autophagosomes into a lysosome creates an unique acidic environment within the cell for
proteolysis and recycling of unneeded cellular components into usable amino acids and other biomolecular
building blocks. In the endocytic pathway, gradual maturation of endosomes into a lysosome and acidification
of the late endosome are accompanied by vesicle trafficking, protein sorting and targeted degradation of
some sorted cargo. Two opposing sorting systems are operating in these processes: the endosomal sorting
complex required for transport (ESCRT) supports targeted degradation and the retromer supports retrograde retrieval
of certain cargo. The endosomal-lysosomal system is emerging as a central player in a host of neurodegenerative
diseases, demonstrating potential roles which are likely to be revealed in pathogenesis and for viable therapeutic
strategies. Here we focus on the physiological process of endosomal-lysosomal maturation, acidification and
sorting systems along the endocytic pathway, and further discuss relationships between abnormalities in the
endosomal-lysosomal system and neurodegenerative diseases, especially Alzheimer’s disease (AD).
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The endosomal-lysosomal system is a series of organ-
elles in the endocytic pathway where various cargo
molecules required for normal cellular function are
internalized, recycled and modulated. Recently, mounting
evidence has suggested that abnormalities in both
endosomes and lysosomes, or dysregulation in their
trafficking, play an important role directly in a sur-
prising host of neurological dysfunctions, represented
by AD, Parkinson’s disease (PD), and Lewy body de-
mentia (LBD) [1–3]. Thus, the endosomal-lysosomal
system is emerging as a key to understanding the
mechanisms underlying both protein degradation and
neurodegeneration. Here, we intend to summarize
advances in the study of the endosomal-lysosomal sys-
tem, with a focus on compartmentalized organization of
trafficking routes, sorting machinery and their relation-
ships to neurodegeneration.
The endosomal-lysosomal system: a dynamic,
interconnected vesicular network
Membrane dynamics which affect protein degradation
and recycling within cells plays a critical role in main-
taining homeostasis. Macromolecules and transmem-
brane proteins at the plasma membrane destined for
degradation could enter the endosomal-lysosomal sys-
tem via three broadly defined routes: endocytosis, au-
tophagy or phagocytosis [4, 5]. Here we focus on the
organization and functions of endocytic trafficking
routes of protein/glycoprotein, and protein-bound lipid
cargoes, preferentially over autophagy or phagocytosis.
The endocytic pathway is composed of a series of
highly dynamic membrane-enclosed tubulo-vesicular
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structures. According to their different functions and
roles in this system, several distinct types of compart-
ments have been identified: early endosomes, recycling
endosomes and late endosomes [6]. Additionally, lyso-
somes serve as organelles for storage of hydrolases, and
are typically considered as a final destination where pro-
teolytic degradation takes place. The membrane bilayer
of endosomes and lysosomes creates an enclosed envir-
onment allowing an acidic pH, which is optimal for
many hydrolases and other enzymes. Compared to a
cytoplasmic pH (of about 7.0), the endosomal and lyso-
somal lumen pH is maintained in a range of 6.5 to 4.5,
due to the activity of the ATP-dependent proton pumps
present in the membrane of both endosomes and lyso-
somes [7]. Molecular trafficking and sorting along the
endocytic pathway is regulated by the Rab family of
small GTPases, which are critically important membrane
association proteins. The Rabs function as molecular
switches that alternate between two conformational
states: the activated GTP-bound form and the GDP-
bound inactivated form [8]. Different Rab proteins
have corresponding host organelles; therefore, they
are often regarded as markers of different endosomal
compartments.
Endosomes are dynamic, specialized compartments
and undergo morphological and biological changes ac-
companied by vesicle trafficking. The maturation model
states that endosomes along the endocytic pathway are
transient and distinct compartments and, endosomes go
through defined stages as they mature [6]. In this model,
the process of endosomal maturation is characterized by
four changes (Fig. 1): (1) an increasing number of intra-
luminal vesicles; (2) an increase in luminal acidification;
(3) movement in space from the cell periphery towards
the microtubule organizing center (MTOC); and (4) the
switching of Rab proteins.
Initially, endocytosis (protein internalization) often
starts at clathrin-coated pits that bud into vesicles de-
rived from the plasma membrane. Within seconds
after their formation, these vesicles can fuse with each
other or with pre-existing early endosomes under the
direction of the small GTPase Rab5 [9]. Early endo-
somes are generally formed in the peripheral cyto-
plasm with a slightly acidic intraluminal pH so that
receptor cargo (ligands) can readily dissociate. The
early endosome acts as a major sorting station, per-
mitting the newly vacated receptors to recycle back to
the cell surface for reuse, and directing dissociated li-
gands to be transported to late endosomes and finally
to lysosomes for degradation. As mentioned, some
membrane receptors along with membrane-bound
lipids are transferred to recycling endosomes, return-
ing to the plasma membrane, and this process is reg-
ulated by Rab4 and Rab11 [10, 11].
As internal vesicles bud inward from the membrane of
the endosome, the number of intralumenal vesicles in-
creases and this is an important transition in the matur-
ation of early endosomes into late endosomes, and is the
process whereby multivescular bodies (MVB) are cre-
ated. The maturation from early to late endosomes is ac-
companied by the transition from association with Rab5
to Rab7, which is also known as “Rab conversion” [12].
Rab7 is a critical regulatory component that regulates
transformation from early-to-late endosomes. In this
process, endosomes move along a microtubule to the
perinuclear region, regulated by interactions with dynein
and kinesin and this process is accompanied by increas-
ing intravacuolar acidification. The central role of late
endosomes involves (1) the biogenesis of intralumenal
vesicles and (2) they serve a role as a sink for sorting of
ubiquitinated membrane proteins for eventual lysosomal
degradation, both of which are executed by the ESCRT
system of ubiquitin interacting and editing complexes
[13]. At last, late endosomes or MVBs fuse with lyso-
somes and cargo proteins and intraluminal vesicles are
degraded. It has been shown that late endosomes can be
major sites of protein hydrolase activity acting on sol-
uble proteins like ovalbumin taken up via earlier endo-
cytosis, surpassing the activity found in lysosomes for
these substrates, and so the entire endosomal-lysosomal
compartment can be considered as a reservoir for hydro-
lases either active or inactive [14, 15]. Moreover, along
the endosomal-lysosomal pathway, the concentration of
acid hydrolases increases, while lumenal pH decreases,
although activity varies by enzyme and not all are most
active against all substrates in the lysosome [14]. In most
neuronal cells, the pH of the lysosomal lumen can be as
low as 4.5 [16]. Within this lumen, there are more than
50 hydrolases concentrated, and some of these show lit-
tle to no sequence homology, suggesting convergent
evolution. The fusion of late endosomes with lysosomes
generally initiates the activation of hydrolase precursors
or proenzymes, with a requirement for intraluminal
Ca2+ and calmodulin [17], and prerequisite glycosyla-
tion with mannose-6-phosphate, which targets the hy-
drolases to receptors that concentrate them in the
endosomal-lysosomal system [14]. Accordingly, lyso-
somes serve as the major site of activation of many
proteolytic activities, even if their activity can be de-
tected in other aspects of the endomembrane system.
The various stages of endocytosis with their branch-
ing decision tree for the sorting of receptors, receptor
cargo, other transmembrane proteins, and hydrolase
enzymes have a fundamental role in both membrane
and protein processing, especially in neurons that re-
quire specialized regulation of endocytic and secretory
pathways to ensure their normal function, particularly
at synapses [18].
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A pH gradient established by vacuolar ATPase
and chloride channels
Vacuolar ATP-dependent acidification
As mentioned above, the endosomal and lysosomal com-
partments share at least one similar significant charac-
teristic: low intraluminal pH. These sealed acidic
compartments provide an appropriate environment for
optimal degradation of substrate cargo and recycling of
their cognate receptors. As macromolecules are trans-
ported along the endosomal-lysosomal pathway, the in-
ternal pH of both endosomes and lysosomes decreases
rapidly due to vacuolar acidification. Previous research
Fig. 1 Endocytosis and endosome maturation. Protein internationalization is often dependent on a ubiquitous clathrin-mediated mechanism. Subsequent
to internationalization, cargo proteins are transported to early endosomes via endocytic vesicles under the control of Rab5. Early endosomes serve as the
major sorting stations where proteins can be sorted into recycling endosomes for recycling back to the cell surface, into a retrogradee pathway mediated
by retromer to be sent back to the trans-golgi network (TGN), or into a degradation pathway for eventual targeting to the lysosome. As the number of
intraluminal vesicles increases, early endosomes mature into late endosomes, and then late endosomes fuse with lysosomes.Due to their different
capacities of acidification, a stable pH gradient is established in different compartments during the maturation process: early endosomes maintain pH at
about 6.5, late endosomes at about 5.5 and lysosomes at about 4.5
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revealed that the same H+-ATPase, also known as vacu-
olar ATPase (V-ATPase), acidifies both endosomes and
lysosomes. V-ATPase, differs from Na+,K+-ATPase in
the plasma membrane, Ca2+-ATPase in the sarcoplasmic
reticulum, and F1,F0-ATP synthase in mitochondria, in
that it does not require a coupled influx of permeant
anions [19]. Sulfhydryl alkylating reagents such as N-
ethylmaleimide inhibit the V-ATPase dependent acid-
ification of the endosomal-lysosomal system [19–21]
as well as the specific inhibitor Bafilomycin A1 [22, 23].
V-ATPase is a unique class of ATPase present
throughout the membranes which constrain the endo-
cytic pathway, including the trans golgi network
(TGN). V-ATPase, as a protein complex, is composed
of two multimeric subunits, V1 in the cytoplasmic do-
main and V0 within the vacuolar membrane; the ac-
tivity of V-ATPase depends on the dynamic assembly
of these. V-ATPase is widely expressed in eukaryotic
cells and serves as the master regulator of vesicular
acidification in many subcellular membrane bound or-
ganelles. It also has important roles to play in vesicu-
lar trafficking and proteostasis.
Chloride channel compensation
Since V-ATPase is electrogenic, continuous proton
influx across membranes would result in an ever-
increasing positive charge buildup in the lumen of
endosomes and lysosomes. Since this potential differ-
ence would constitute an energetic barrier to main-
tenance of acidification, it is apparent that vacuoles
must have a means of compensating. A series of
studies have identified that chloride channels (CLC)
conduct passive Cl− ion current, which compensates
for proton accumulation by V-ATPase [24, 25]. In
mammals, CLC proteins form a large family of nine
members and among them, CLC3 to CLC7 localize
to membranes of the endosomal-lysosomal system.
These vesicular CLCs are thought to stimulate V-
ATPase activity in endosomal-lysosomal compart-
ments, thereby facilitating acidification. To do this,
CLCs permit H+ influx against a concentration gra-
dient, but compensate by minimizing the electro-
chemical gradient, resulting in net regulation of the
pH of vesicular compartments. In turn, CLC ion cur-
rents are regulated by the state of the intraluminal
environment: for example, low lumenal pH is able to
open CLC channel gating and Cl− currents. Even
though there are still controversies over the import-
ance of CLCs, a number of studies have provided
evidence that CLC defects in the nervous system of
mice led to endosomal pH elevation, and dysfunc-
tional cellular protein degradation, causing pheno-
types very similar to human neurodegenerative
diseases, like AD and PD [26, 27].
Functions mediated by acidification
An acidic lumenal environment is necessary for proper
function as follows [14]: (1) internalized receptors need
acidic conditions in order to release their ligands and re-
cycle back to the membrane; (2) the pH gradient along
the endosomal-lysosomal pathway might direct the
movement and maturation of these organelles [15];
(3) many hydrolases have optimal function at acidic
pH; (4) acidic pH conditions may produce an envir-
onment favorable to oxidation reactions within the
endosomal-lysosomal system.
Two opposing cargo sorting systems: the retromer
and ESCRT
On entering the endosomal-lysosomal network, inter-
nalized protein cargo has two potential destinies:
either it is trafficked and delivered to the late endo-
somes and terminally, to lysosomes for degradation
(via the ESCRT system); or, it is sorted and trans-
ported to the TGN or the plasma membrane for re-
use (via the retromer).
ESCRT: sorting ubiquitinated proteins for degradation
In the pathway promoting degradation, cargo proteins
are transported into the intralumenal vesicles of endo-
somes for subsequent degradation. This process is initi-
ated by a cargo-sorting receptor, namely ESCRT, such
that target proteins are first captured in a signal-
dependent manner. At the endosomal membrane, it is
now evident that the ESCRT complexes serve to
recognize and sort ubiquitinated endosomal proteins for
degradation [13]. The machinery and molecular basis of
this ubiquitin-dependent endosomal sorting is emerging
through many studies in yeast as well as mammalian
cells, some of which we highlight below.
The ESCRT machinery consists of four distinct protein
complexes: ESCRT-0, I, II, and III, named for their order
of recruitment and function in triggering ubiquitin-
dependent sorting of cargo proteins into the MVBs of
endosomes [28]. Advances in biochemistry and cell biol-
ogy have provided a good picture of the architecture and
interactions of the ESCRTs. The “conveyor belt model”
for ESCRT complex function proposes that these com-
plexes function sequentially to sort ubiquitinated pro-
teins into MVBs, starting with ESCRT-0 and ending
with ESCRT-III.
ESCRT-0, the least evolutionarily conserved of the
ESCRT complexes, contains multiple ubiquitin-binding
subunits or activities and is able to retain ubiquitylated
proteins in or at the endosomal membrane, but its affin-
ity for ubiquitin is very low. It is, however, able to sup-
port the clustering of ubiquitinated membrane receptors
into patches of membrane, thereby increasing the local
concentration of such receptors. Once ESCRT-0 has
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bound to an ubiquitinated protein, ESCRT-I, which has
higher affinity, can take on the role of binding to the
ubiquitinated substrate protein. ESCRT-I as well as
ESCRT-II each have just one ubiquitin-binding domain,
so that it is hypothesized they require ESCRT-0 for con-
centration of ubiquitin-tagged cargo prior to their bind-
ing [13]. ESCRT-III comprises several small, highly
charged subunits, assembling in a highly ordered man-
ner. The ESCRT-III complex has moonlighting roles in
cytokinesis and viral budding, but is known to harbor
deubiquitinase activity that acts to release ubiquitin from
substrates successfully moving down the ESCRT
conveyor. ESCRT-III also has functions in the genesis of
MVBs by supporting invagination and pinching off of
the endosomal membrane in regions that have seques-
tered cargo [29, 30].
Retromer: a singular path for retrograde retrieval
Over the past couple of decades, there has been an in-
creasing body of evidence implicating an ancient, evolu-
tionarily conserved eukaryotic complex, which has come
to be termed the “retromer.” The primary function of
the retromer is to conduct multiple cargo-sorting events,
mediating retrograde retrieval from endosomes to the
TGN [31]. In yeast, the retromer is comprised of five
subunits, all encoded by vacuolar protein sorting (VPS)
genes: Vps35-Vps29-Vps26 are a trimeric core, while
Vps5-Vps17 is a dimer of sorting nexin (SNX) proteins.
Even though SNX proteins differ significantly between
species, the trimeric protein is highly conserved, which
is also named the cargo-selective complex (CSC) for its
role in recognizing cargo proteins [32]. In this recycling
pathway, the principal cargoes of retrieval are unli-
ganded receptors that may have been missorted to
lysosomes.
Even though there remain significant gaps in our un-
derstanding of specific mechanisms of retrograde traf-
ficking, it is clear that, as pioneering studies have
indicated, the retromer has cargo-specific recognition
capacity, and that there are different forms of the com-
plex acting on distinct sets of cargo through CSC associ-
ation with different sorting nexins [33]. It is notable that
the CSC trimer, despite its role as the core functional
component of the retromer complex, has no membrane-
binding activity and relies on nexins or Rab7 to execute
its functions directed at membrane bound cargo. Previ-
ously, Vps35 was thought to provide the sole interface
for cargo recognition, but recent studies have shown
that other proteins such as Vps26, SNX3, and SNX27,
are also implicated in cargo recognition in mammalian
cells [31]. The sorting nexins recruit the CSC to
endosomes and mediate its binding to the endosomal
membrane. For example, SNX3, specifically recogniz-
ing phosphatidylinositol-3-monophosphate (which is
enriched in early endosomes), can target the CSC to
this compartment.
Abnormalities and dysregulation of the
endosomal-lysosomal system in
neurodegeneration
Increasing attention being paid to the endosomal-
lysosomal system has begun to elucidate a relationship
between endosomal-lysosomal defects and neurodegen-
eration. In particular, robust pathology implicating
endosomal-lysosomal disruption in AD has been well
characterized. Here, we focus preferably on AD as a ex-
ample of neurodegenerative disease and we believe that
AD represents a general model of neurodegenerative dis-
eases on abnormalities of the endosomal-lysosomal sys-
tem occur along a continuum that includes early
endosome changes, dysregulated acidification and sort-
ing component defects (Fig. 2).
“APP, in the early endosome, with beta secretase”:
accomplices and bystanders
Even though many details remain to be resolved, a strik-
ing body of evidence indicates that disturbed vesicular
trafficking has special relevance in AD and other neuro-
degenerative diseases [3]. In particular, as just described,
early endosomes mark the location of initial amyloido-
genic processing of APP by beta-site APP cleaving en-
zyme 1 (BACE1) and dissociation of ApoE from its
receptor, LDLR1, upon internalization and the extent to
which these events occur is dependent upon the time of
residence in this compartment, thus attracting much at-
tention. ApoE and its receptor genetically and function-
ally interact with APP, to influence its endocytosis and
degradation [34, 35], thereby modulating the severity of
amyloid pathogenesis.
Studies have demonstrated that BACE1 and APP pro-
teolytic fragments, Aß and carboxyl-terminal APP frag-
ment by BACE1 (ßCTF) are abundant in early
endosomes [1, 36, 37]. For example, in cell models of
AD pathology, the ßCTF has been found to be accumu-
lated in early endosomes and it can disrupt neuronal
ionic homeostasis in a concentraction-dependent man-
ner [38]. Meanwhile, the dysfuction of BACE1 retro-
grading from the endosomes into the TGN, appears
to enhance the production of ßCTF, leading to an in-
crease of Aß in early endosomes. In the brains of AD
patients, Cataldo et al. found that, even at earliest
stage of disease when neurons exhibit enlarged Rab5-
positive endosomes containning Aß immnoreactivity
[39]. Moreover, Aß1-42 may also accumulate in lyso-
somes, disrupting the lysosomal membrane [40]. As a
consequence, it has been noted that ectopic, elevated
levels of lysosomal hydrolases can be observed in the
CSF of individuals with AD [41]. It was first reported
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almost two decades ago that in familial AD, Rab5 is over-
expressed or stabilized post-translationally concommitant
with a very marked increase in pyramidal neuron early
endosome volume, and this results in increased proc-
essing of APP, a sorting imbalance, and decreases in
neurotrophin receptor expression [42, 43]. Enlarge-
ment of the early endosome compartment has been
considered as the earliest pathological change in AD,
even occurring decades before clinical symptoms are
evident [44]. Further, swollen endosomal profiles have
been postulated to represent activation of the endosomal-
lysosomal pathway, involving increased rates of endocyto-
sis and vesicular turnover. Consistent with this, studies
using Rab5 as a specific endosomal marker have identified
Fig. 2 The endosomal–lysosomal system and AD. (i) endosomal enlargement, Rab5 overexpression and Aß accumulation; (ii) dysregulated
endosomal-lysosomal acidification, pH elevation and tau aggregation; (iii) dysfunctional ESCRT complexes, defective autophagy and accumulation
of intraluminal ubiquitinated proteins; (iv) defects of retromer: reduction of Vps26, Vps35 and SorLA disrupts the trafficking and processing of APP
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a relationship between increased endocytosis and an en-
largement in endosome size and volume [45]. Interest-
ingly, a number of Rabs that regulate the flux of traffic
through early endosomes directly or in adjacent compart-
ments have been found by RNAi screen to be either
positive or negative regulators of Aß production in heter-
ologous mutant APP expressing cell lines [46]. Another
recent review that delves into effects of interactors in
regulating traffic of APP and secretases, particularly con-
sidering events increasing their co-location throughout
the endomembrane system as opportunities for alternative
APP processing events [47].
Even though it is established that AD is a heteroge-
neous disease, perturbation of the neuronal endosomal-
lysosomal pathway is one cellular feature shared in
common by all subtypes of AD. Therefore, it is tempting
to speculate that cellular pathological changes affecting
this system are early and essential initiating events in
AD pathogenesis, regardless of disease subtype and gen-
etic predisposition.
Dysregulated acidification, cellular indigestion?
Endosomal-lysosomal pH defects are an emerging theme
in mechanisms underlying a number of neurodegenera-
tive diseases. To date, results from experiments in vivo
and in vitro have revealed the importance of proper
vesicular pH balance and optimal acidification in trans-
porting and degrading cargo via the endocytic pathway
[48, 49]. For instance, Lee et al. reported that, in preseni-
lin1 (PSEN1)-deleted blastocysts, defective lysosome
acidification was observed with a substaintially elevated
lysosomal PH of 5.4 and PSEN1 is essential for the
transport of mature V0a1 subunites of V-ATP to lyso-
somes for their acidification and proteolysis [50]. Specif-
ically, dysregulation of acidification and intracellular pH
perturbation could influence the activity of enzymes in
endomembrane compartments, resulting in impaired
clearance of protein aggregates downstream of elevated
endomembrane system pH, or conversely, due to de-
creased cytoplasmic pH. Regarding the latter, asparaginyl
endopeptidase (AEP) is a typical pH-sensitive protein
hydrolase the activity of which depends on the acidic pH
of vesicular compartments. Predominantly localized in
late endosomes, asparaginyl endopeptidase (AEP) specif-
ically cleaves substrates with an asparagine residue at
the P1 site. It is known that AEP can undergo reversible
pH-dependent autoproteolytic activation, and in normal
conditions, full-length pro-AEP is inactive [51]. As pH
decreases from neutral to acidic, the activity of AEP
gradually increases, such that it is partially activated at
pH 4.5 and fully activated at pH 3.5, via removal of a
cap that covers the active site. In AD patients, lysosomal
acidification may be defective and it has been shown
that the intracellular pH of neurons gradually decreases
with aging [52] and more so with lactic acid elevation
seen in AD cortex [53], so ectopic AEP activation or ac-
tivity after leakage of active enzyme from late endosomes
or lysosomes may be increased. AEP is involved in
pathological tau degradation. Specifically, AEP gener-
ates tau fragments that form insoluble fibrils and re-
sult in neurotoxicity and neuropathological changes in
AD [54, 55].
Increased endosome and lysosome pH is expected to
have global effects on the proteome, particularly mem-
brane proteins which rely on this pathway for their regu-
lation and degradation. Interestingly, studies of microglia
in culture have shown that in the absence of inflamma-
tory IL-6 signaling, microglia do not achieve a suffi-
ciently low lysosomal pH to degrade Aß, while after
stimulation, CLC7 trafficking to lysosomes increases and
pH drops sufficiently to improve Aß clearance [49, 56].
We have recently performed a systematic look at the
proteomic effects of defective endosomal-lysosomal pH
in a cellular model, in order to develop a better under-
standing of the global changes in the proteome that fol-
low inhibition of V-ATPase and could be considered
together as a signature or biomarker of defective vacu-
olar acidification [57, 58], which would be expected to
have an overlap with changes seen in AD and/or other
conditions which may be subject to this often age-
dependent defect. Indeed, blocking lysosomal degrad-
ation with bafilomycin A1 affects a significant increase
in global K63 polyubiquitin linkages, which also occurs
in AD, but AD brain global ubiquitin linkage profiling
shows changes in other linkages as well [59]. Since K63
linked ubiquitin is not targeted to the proteasome, but
does increase with V-ATPase acidification in the model
of lysosomal insufficiency, the increase in K63 linkages
seen in AD implicates accumulation of ubiquitinated
proteins with obligate ESCRT-mediated degradation.
Thus, trafficking, inflammatory signaling, and cell-type
specific roles of dynamic lysosomal acidification are be-
coming increasingly appreciated for potential roles in
AD pathogenesis.
Roles of sorting components in AD
The ESCRTs
A number of neurodegenerative diseases, including AD,
are characterized by accumulation of intracellular ubi-
quitinated proteins which can be actively collected into
aggregates that are usually targeted to autophagosomes,
thus implicating defective autophagy. The ESCRT com-
plexes are involved in multiple cellular processes, includ-
ing efficient fusion of autophagic vesicles for bulk
degradation of cargo proteins. Autophagy serves as an
intracellular clearance mechanism, preventing the accu-
mulation of proteins that disrupt neuronal function and
eventually lead to neurodegeneration [60, 61].
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Interestingly, in early stages of AD, autophagy in neu-
rons is activated, but becomes compromised as the dis-
ease progresses. There are more and more studies to
identify the signal molecular machinery involving au-
tophagy and the ESCRTs. Studies indicate that the
ESCRT machinery is not only involved in sorting ubiqui-
tinated cargo but also in initiating vesicle formation
within endosomes becoming MVBs [62]. The most dir-
ect evidence for an ESCRT role in protection of neurons
from protein accumulation and neurodegeneration has
been seen upon overexpression of charged multivesicular
body protein 2B (CHMP2B), which is a subunit of the
ESCRT-III complex. CHMP2B overexpression in neu-
rons impairs lysosomal degradation of internalized pro-
teins, resulting in accumulation of autophagosome,
dendritic retraction and neuronal loss [63]. Typically,
the autophagic pathway converges with the endocytic
pathway at a point where mature autophagosomes fuse
with MVBs. Compromised ESCRT function blocks the
maturation and the proper turnover of autophagosomes,
while functional ESCRT complexes are required for au-
tophagic fusion and efficient degradation [64, 65].
The retromer
Over the years, researchers have studied neurodegenera-
tive diseases arising from defects of retromer sorting
proteins [66–68]. Particular interest has been taken in
the link between retromer function to AD pathogenesis
[69]. First, it was proposed that the retromer mediates
endosome-to-TGN traffic of beta secretase, particularly
BACE1, a transmembrane protein and enzyme that
cleaves APP, promoting amyloidogenic and neurotoxic
release of the ßCTF that is the precursor of Aß species,
as well as the C-terminal fragment APP intracellular do-
main (AICD), and this event is considered to be up-
stream of neurotoxic effects resulting from BACE1
activity [70]. Dysfunction of the retromer increases the
concentration of BACE1 in the endosomal compart-
ments, thereby providing more of an opportunity for the
cleavage of APP, Aß production and ultimately,extracel-
lular Aß-containing plaques [66, 71]. In the brains of pa-
tients with AD, expression of Vps26 and Vps35 is
reduced. Since these are two critical components of the
retromer CSC trimer that recognize retromer cargo in-
cluding BACE1, loss of function for the CSC would be
expected to promote amyloidogenesis. Indeed, another
study found that Vps35 mutation leads to up-regulation
of Aß generation in mouse models [72]. Stabilizing the
retromer complex via a drug-like chemical chaperone
was found to decrease Aß production and increase neu-
roprotective alpha cleavage, probably by shifting APP
out of early endosomes and improving functional retro-
mer complex levels [73].
Interestingly, the above mentioned chemical chaperone
also shifted the localization of SorLA, which associates
with both Vps26 and APP, modulating amyloidogenic
cleavage of APP [74] by upregulating the sorting of APP
into endosomal compartments [75]. Recently, a compre-
hensive study proved that reduced SorLA expression is as-
sociated with mild cognitive impairment (MCI) and AD
[76]. In cultured hippocampal neurons, studies have
confirmed important roles of SorLA in trafficking and
processing of APP. SorLA direct Aß peptides to late endo-
somes and lysosomes, consequently, promoting degrad-
ation and clearance [77, 78].
Finally, it is important to point out that the general
processes of endocytosis and endosomal-lysosomal dys-
regulations above-mentioned, have profoundly distinct
implications for potential functions associated with other
neurodegenerative diseases, such as PD, ALS, and
Frontotemporal lobe degeneration (FTLD).
Conclusions and perspective
The endosomal-lysosomal system is a complex and
highly dynamic process, where internalized transmem-
brane proteins, receptors, receptor ligands, and some
soluble extracellular proteins are transported, sorted,
and/or degraded. In recent years, particular attention
has been paid to the endosomal-lysosomal system be-
cause it is involved in almost all of the neurodegenera-
tive diseases, even though how it does so in each still
remains unclear. Ongoing future studies will investigate
both common and cell-type (or even local membrane
region) specific trafficking and proteostasis pathways in-
volving the endosomal-lysosomal system as well as the
larger endomembrane system. For example, a better
understanding of distinct roles that ubiquitination
plays in ESCRT-mediated proteostasis (and even lipid
droplet homeostasis [79] which appears to be dysreg-
ulated in glia in neurodegeneration [47, 80]) could
help to predict and ultimately therapeutically address
the onset and progression of neurodegenerative dis-
eases for specific individuals or sub-populations. This
milieu of membrane-bound proteins that dynamically
sorts cargo enriched for signaling, inflammation, and
neurotrophic functions—among others—promises to
provide a mother lode of new therapeutic targets for
amelioriating neurodegenerative diseases, but the ex-
ploration also promises to be challenging, requiring
the development of novel techniques and insight.
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